Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,689 JPY
Change Today +82.00 / 5.10%
Volume 187.8K
4559 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
As of 2:00 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

zeria pharmaceutical co ltd (4559) Snapshot

Open
¥1,648
Previous Close
¥1,607
Day High
¥1,698
Day Low
¥1,635
52 Week High
09/1/14 - ¥2,551
52 Week Low
08/25/15 - ¥1,497
Market Cap
89.7B
Average Volume 10 Days
171.6K
EPS TTM
¥45.20
Shares Outstanding
53.1M
EX-Date
09/28/15
P/E TM
37.4x
Dividend
¥30.00
Dividend Yield
1.78%
Current Stock Chart for ZERIA PHARMACEUTICAL CO LTD (4559)

Related News

No related news articles were found.

zeria pharmaceutical co ltd (4559) Related Businessweek News

No Related Businessweek News Found

zeria pharmaceutical co ltd (4559) Details

Zeria Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents. The company also provides cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, and analytical equipment. Its ethical pharmaceutical products include functional dyspepsia treatment products, histamine h2 receptor antagonists, zinc containing anti-ulcerants, oral bowel cleansing products, laxative products, ulcerative colitis remedies, and proton pump inhibitors in the gastrointestinal field. The company’s products also include hypophosphatemia treatment products, long-acting calcium channel blockers, absorbable topical hemostats, sclerotherapy products for leg varicose veins, enzymatic hemostatics, anti-platelet oral jellies, oral non-steroidal anti-inflammatory products, anti-leukopenia after radiotherapy products, topical non-steroidal anti-inflammatory products, anti-inflammatory topical blood circulation enhancers, and non-steroidal anti-inflammatory ophthalmic solutions. In addition, Zeria Pharmaceutical Co., Ltd. offers OTC drugs and products, such as self-prevention products, remedies for gastrointestinal diseases, dermal remedies/cosmeceuticals, ophthalmic solutions, cold remedies, nutrient tonics, and topical anti-inflammatory analgesics. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

1,426 Employees
Last Reported Date: 06/26/15
Founded in 1955

zeria pharmaceutical co ltd (4559) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeria pharmaceutical co ltd (4559) Key Developments

Zeria Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended June 30, 2015; Provides Earning Guidance for the First Half and Full Year of Fiscal 2016

Zeria Pharmaceutical Co., Ltd. announced earnings results for the first quarter ended June 30, 2015. The company has reported that profit attributable to owners of parent for the first quarter ended June 30, 2015 was JPY 891 million, or JPY 16.79 per basic share, compared to JPY 1.05 billion, or JPY 19.74 per basic share, for the same quarter ended June 30, 2014. Net sales for the first quarter ended June 30, 2015 were JPY 14.72 billion, compared to JPY 14.71 billion for the same quarter ended June 30, 2014. Operating income for the first quarter ended June 30, 2015 was JPY 1.03 billion, compared to JPY 858 million for the same quarter ended June 30, 2014. For the first six months of fiscal year ending March 31, 2016, the company expects profit attributable to owners of the parent to be JPY 1.10 billion and earnings per basic share to be JPY 20.71. For the first six months of fiscal year ending March 31, 2016, the company expects operating income to be JPY 1.60 billion, net sales to be JPY 31 billion and ordinary income to be JPY 1.10 billion. For the fiscal year ending March 31, 2016, the company expects profit attributable to owners of the parent to be JPY 3.0 billion, earnings per basic share to be JPY 56.48, operating income to be JPY 4.0 billion and net sales to be JPY 65 billion.

Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Half Year and Full Year Ending March 31, 2016

Zeria Pharmaceutical Co., Ltd. provided dividend guidance for the half year and full year ending March 31, 2016. For the half year, the company expects to pay a dividend of JPY 15 per share. For the full year, the company expects to pay year-end dividend of JPY 15 per share.

Zeria Pharmaceutical Co., Ltd. to Report Q1, 2016 Results on Aug 05, 2015

Zeria Pharmaceutical Co., Ltd. announced that they will report Q1, 2016 results on Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4559:JP ¥1,689.00 JPY +82.00

4559 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4559.
View Industry Companies
 

Industry Analysis

4559

Industry Average

Valuation 4559 Industry Range
Price/Earnings 37.6x
Price/Sales 1.5x
Price/Book 1.5x
Price/Cash Flow 37.6x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZERIA PHARMACEUTICAL CO LTD, please visit www.zeria.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.